Navigation Links
Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting

SAN DIEGO, May 19, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data from a completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented in an Oral Abstract Session at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Sunday, June 5, 2011.

Presentation details are as follows:Presentation Title:

Safety, Pharmacokinetics, and Pharmacodynamics Results From a Phase 1 Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, In Patients with Advanced Cancer Session Type/Title:

Oral Abstract Session: Developmental Therapeutics – Experimental Therapeutics Author/Presenter:

Colin Weekes, MD, PhD – Assistant Professor, Division of Medical Oncology, University of Colorado School of MedicineAbstract ID:


Sunday, June 5, 2011 from 9:30 AM – 12:30 PM CDTAbout BAY 86-9766BAY 86-9766 (RDEA119) is a potent and highly selective inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer Healthcare (Bayer). Preclinical and clinical data suggest that BAY 86-9766 has favorable properties, including once-daily oral dosing and excellent selectivity. In addition, BAY 86-9766 has been shown to suppress tumor cell growth in vitro and in vivo. Preclinical in vitro and in vivo oncology studies of BAY 86-9766 have demonstrated significant potential synergy across multiple tumor types when used in combination with other anti-cancer agents, including sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals, Inc.).

About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.



SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
2. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Ardea Biosciences to Present at Two Upcoming Investor Conferences
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
10. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International ... and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. ... 2015, where ISPE hosted the largest number of attendees in more than a ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced ... 29, 2015 at 11:00 a.m. Israel time, at ... 98 Yigal Allon Street, 36 th Floor, Tel Aviv, ... Eric Paneth and Izhak Tamir to the Board of ... as external directors; , approval of an amendment to certain terms ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading ... culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... on the management team and was promoted to Head of InSphero Diagnostics ...
Breaking Biology Technology:
(Date:10/26/2015)... PUNE, India , October 26, ... --> --> ... Forecasts 2015 to 2021 as well ... Analysis 2015-2019 research reports to its ... . ...
(Date:10/23/2015)... Research and Markets ( ) has ... Biometrics Market 2015-2019" report to their offering. ... global voice recognition biometrics market to grow at a ... --> --> The report, Global Voice ... an in-depth market analysis with inputs from industry experts. ...
(Date:10/22/2015)... Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a ... its first quarter ended September 30, 2015. ... of fiscal 2016 grew 66 percent over the comparable quarter last ... fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... for the first quarter of fiscal 2016 grew 39 percent over ...
Breaking Biology News(10 mins):